How to buy Salarius Pharmaceuticals stock | $1.08

Salarius Pharmaceuticals, Inc is a biotechnology business based in the US. Salarius Pharmaceuticals shares (SLRX) are listed on the NASDAQ and all prices are listed in US Dollars. Salarius Pharmaceuticals employs 7 staff and has a trailing 12-month revenue of around USD$4.8 million.

How to buy shares in Salarius Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Salarius Pharmaceuticals. Find the stock by name or ticker symbol: SLRX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Salarius Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$1.08, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Salarius Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Salarius Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Salarius Pharmaceuticals share price

Use our graph to track the performance of SLRX stocks over time.

Salarius Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-12-09.

Latest market close	USD$1.08
52-week range	USD$0.5552 - USD$4.98
50-day moving average	USD$0.7604
200-day moving average	USD$1.0411
Wall St. target price	USD$4.43
PE ratio	1.803
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-176.437

Buy Salarius Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Salarius Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Salarius Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Salarius Pharmaceuticals price performance over time

Historical closes compared with the close of $1.08 from 2020-12-09

1 week (2021-01-07)	-0.92%
1 month (2020-12-15)	28.88%
3 months (2020-10-15)	27.66%
6 months (2020-07-15)	-25.00%

1 year (2020-01-15)	-64.71%
2 years (2019-01-15)	217.18%
3 years (2018-01-13)	N/A
5 years (2016-01-15)	9.8

Is Salarius Pharmaceuticals under- or over-valued?

Valuing Salarius Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Salarius Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Salarius Pharmaceuticals's P/E ratio

Salarius Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Salarius Pharmaceuticals shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Salarius Pharmaceuticals financials

Revenue TTM	USD$4.8 million
Gross profit TTM	USD$-553,896
Return on assets TTM	-19.92%
Return on equity TTM	-49.22%
Profit margin	-155.8%
Book value	$1.04
Market capitalisation	USD$21.5 million

TTM: trailing 12 months

Shorting Salarius Pharmaceuticals shares

There are currently 585,014 Salarius Pharmaceuticals shares held short by investors – that's known as Salarius Pharmaceuticals's "short interest". This figure is 3% up from 567,997 last month.

There are a few different ways that this level of interest in shorting Salarius Pharmaceuticals shares can be evaluated.

Salarius Pharmaceuticals's "short interest ratio" (SIR)

Salarius Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Salarius Pharmaceuticals shares currently shorted divided by the average quantity of Salarius Pharmaceuticals shares traded daily (recently around 130875.61521253). Salarius Pharmaceuticals's SIR currently stands at 4.47. In other words for every 100,000 Salarius Pharmaceuticals shares traded daily on the market, roughly 4470 shares are currently held short.

However Salarius Pharmaceuticals's short interest can also be evaluated against the total number of Salarius Pharmaceuticals shares, or, against the total number of tradable Salarius Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Salarius Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Salarius Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0303% of the tradable shares (for every 100,000 tradable Salarius Pharmaceuticals shares, roughly 30 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Salarius Pharmaceuticals.

Find out more about how you can short Salarius Pharmaceuticals stock.

Salarius Pharmaceuticals share dividends

We're not expecting Salarius Pharmaceuticals to pay a dividend over the next 12 months.

Have Salarius Pharmaceuticals's shares ever split?

Salarius Pharmaceuticals's shares were split on a 1:25 basis on 22 July 2019. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Salarius Pharmaceuticals shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Salarius Pharmaceuticals shares which in turn could have impacted Salarius Pharmaceuticals's share price.

Salarius Pharmaceuticals overview

Salarius Pharmaceuticals, Inc. a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals, Inc. has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Frequently asked questions

• What percentage of Salarius Pharmaceuticals is owned by insiders or institutions?

  Currently 5.395% of Salarius Pharmaceuticals shares are held by insiders and 26.254% by institutions.

• How many people work for Salarius Pharmaceuticals?

  Latest data suggests 7 work at Salarius Pharmaceuticals.

• When does the fiscal year end for Salarius Pharmaceuticals?

  Salarius Pharmaceuticals's fiscal year ends in December.

• Where is Salarius Pharmaceuticals based?

  Salarius Pharmaceuticals's address is: 2450 Holcombe Boulevard, Houston, TX, United States, 77021

• What is Salarius Pharmaceuticals's ISIN number?

  Salarius Pharmaceuticals's international securities identification number is: US79400X1072

• What is Salarius Pharmaceuticals's CUSIP number?

  Salarius Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 33938A105